[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:mild-dementia:amyloid":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Mild dementia","Amyloid",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07169578","A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease",[12],"Phase 3","RECRUITING","2026-08-26T02:18:36.226508Z","2026-05-05T02:43:29.054228Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07170150","A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease",[12],"2026-08-26T02:18:57.189473Z","2026-04-29T02:57:57.175631Z",{"nct_id":23,"title":24,"phases":25,"status":27,"updated_at":28,"content_modified":29},"NCT06723015","Tau PET Outcomes With Anti-amyloid Immunotherapies",[26],"Phase 2","ENROLLING_BY_INVITATION","2026-08-26T02:18:37.277498Z","2026-06-16T05:54:07.768381Z"]